|
1）Tanabe N, Taniguchi H, Tsujino I, et al. Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology. 2015; 20: 805-12
|
|
|
|
2）Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62: D34-41
|
|
|
|
|
|
3）Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62: D109-16
|
|
|
|
|
|
4）Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980; 93: 391-8
|
|
|
|
|
|
5）Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981; 317: 681–6
|
|
|
|
|
|
6）Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008; 32: 619-28
|
|
|
|
|
|
7）Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009; 3: 15-21
|
|
|
|
|
|
8）King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184: 92-9
|
|
|
|
|
|
9）Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158: 641-9
|
|
|
|
|
|
10）Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014; 190: 208-17
|
|
|
|
|
|
11）Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev. 2009; 18: 35-41
|
|
|
|
|
|
12）Alp S, Skrygan M, Schmidt WE, et al. Sildenafil improves hemodynamic parameters in COPD--an investigation of six patients. Pulm Pharmacol Ther. 2006; 19: 386-90
|
|
|
|
|
|
13）Madden BP, Sheth A, Wilde M, et al. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease? Vascul Pharmacol. 2007; 47: 184-8
|
|
|
|
|
|
14）Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J. 2008; 31: 759-64
|
|
|
|
|
|
15）Rao RS, Singh S, Sharma BB, et al. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci. 2011; 53: 81-5
|
|
|
|
|
|
16）Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012; 9: 268-75
|
|
|
|
|
|
17）Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013; 42: 982-92
|
|
|
|
|
|
18）The Idiopathic Pulmonary Fibrosis Clinical Research Network. A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis. N Engl J Med. 2010; 363: 620-8
|
|
|
|
|
|
19）Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013; 143: 1699-708
|
|
|
|
|
|
20）Zimmermann GS, von Wulffen W, Huppmann P, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology. 2014; 19: 700-6
|
|
|
|
|
|
21）Hoeper MM1, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013; 41: 853-60
|
|
|
|
|
|
22）Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013; 41: 1292-301
|
|
|
|
|